Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer

RATIONALE: It is now standard for most breast cancer patients with 1-2 positive sentinel nodes to avoid completion node dissection when eligibility criteria from the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial are met. The National Comprehensive Cancer Network (NCCN) recently proposed to extend this indication to patients that present with biopsy proven node positive disease if only 1 or 2 suspicious nodes are found on imaging, these positive nodes are not palpable clinically, and the other eligibility criteria from the Z0011 study are otherwise met. However, this recommen

Trial Details

NCT ID
NCT04671511
Phase
NA
Sponsor
Jewish General Hospital
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Targeted Axillary Dissection
  • Ultrasound of the axilla
Locations (sample)
  • Montreal, Quebec, Canada|45.50884,-73.58781
  • Montreal, Quebec, Canada|45.50884,-73.58781
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Participants must be ≥ 18 years old.
  • Participants with a clinical T1 or T2 invasive ductal or lobular breast carcinoma, regardless of estrogen/progesterone/human epidermal growth facto…
  • Participants with clinical (on palpation) N0 and up to two suspicious lymph nodes on axillary ultrasound.
  • Participant with biopsy-proven positive axillary disease made by core needle biopsy or fine-needle aspiration.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →